Ginkgo Bioworks Holdings, Inc. (NYSE:DNA – Get Free Report) insider Mark E. Dmytruk sold 47,806 shares of the firm’s stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $0.84, for a total transaction of $40,157.04. Following the completion of the sale, the insider now owns 925,400 shares in the company, valued at approximately $777,336. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
Ginkgo Bioworks Price Performance
Shares of DNA stock traded up $0.03 on Monday, reaching $0.99. 30,732,457 shares of the company were exchanged, compared to its average volume of 28,135,193. The company has a 50-day moving average of $1.08 and a 200-day moving average of $1.31. The company has a market cap of $2.13 billion, a price-to-earnings ratio of -2.17 and a beta of 1.42. Ginkgo Bioworks Holdings, Inc. has a one year low of $0.74 and a one year high of $2.55.
Ginkgo Bioworks (NYSE:DNA – Get Free Report) last issued its quarterly earnings data on Thursday, February 29th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.01). Ginkgo Bioworks had a negative net margin of 355.08% and a negative return on equity of 48.23%. The business had revenue of $34.76 million for the quarter, compared to analyst estimates of $40.37 million. During the same quarter in the prior year, the business earned ($0.04) earnings per share. The firm’s quarterly revenue was down 64.6% compared to the same quarter last year. As a group, sell-side analysts predict that Ginkgo Bioworks Holdings, Inc. will post -0.32 EPS for the current year.
Analysts Set New Price Targets
Check Out Our Latest Stock Report on DNA
Hedge Funds Weigh In On Ginkgo Bioworks
Hedge funds have recently bought and sold shares of the company. Spire Wealth Management bought a new stake in Ginkgo Bioworks during the fourth quarter worth $25,000. Prime Capital Investment Advisors LLC bought a new position in Ginkgo Bioworks during the fourth quarter valued at $37,000. Stratos Wealth Partners LTD. purchased a new stake in Ginkgo Bioworks in the third quarter worth $43,000. Smith Salley & Associates raised its stake in shares of Ginkgo Bioworks by 100.0% in the fourth quarter. Smith Salley & Associates now owns 24,000 shares of the company’s stock valued at $41,000 after buying an additional 12,000 shares during the period. Finally, Headlands Technologies LLC purchased a new position in shares of Ginkgo Bioworks during the 3rd quarter valued at $53,000. 78.63% of the stock is owned by hedge funds and other institutional investors.
About Ginkgo Bioworks
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.
See Also
- Five stocks we like better than Ginkgo Bioworks
- The How and Why of Investing in Gold Stocks
- 3 CEO-Led Turnaround Stocks You Can Still Buy
- Market Cap Calculator: How to Calculate Market Cap
- 3 Value Stocks You Can Buy Before They Become Big
- Earnings Per Share Calculator: How to Calculate EPS
- Chinese Stocks Stage Impressive Rebound
Receive News & Ratings for Ginkgo Bioworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ginkgo Bioworks and related companies with MarketBeat.com's FREE daily email newsletter.